

# Information for Connecticut Prescribers of Prescription Drugs

## Omvo<sup>™</sup> (mirikizumab-mrkz)

- Connecticut Public Act No. 23-171 requires “pharmaceutical representatives” (as defined in the Act) provide certain information to prescribers and pharmacists. The information in this disclosure is being provided pursuant to this Act.
- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.

### Product:

| BRAND NAME        | GENERIC NAME     | STRENGTH   | DOSAGE FORM        | PACK SIZE | NDC          | WHOLESALE ACQUISITION COST <sup>1</sup> |
|-------------------|------------------|------------|--------------------|-----------|--------------|---|
| Omvo <sup>™</sup> | mirikizumab-mrkz | 300MG/15ML | Vial               | 1         | 0002-7575-01 | \$9,593.22                              |
|                   |                  | 100MG/ML   | Pre-filled Pen     | 2         | 0002-8011-27 | \$10,360.67                             |
|                   |                  | 100MG/ML   | Pre-filled Syringe | 2         | 0002-8870-27 | \$10,360.67                             |

Omvo<sup>™</sup> and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

<sup>1</sup> Source: AnalySource®. Accessed on 5/29/2024. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2024. <http://www.fdbhealth.com/policies/drug-pricing-policy/>.